Gene Editing Stock’s Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
Credit Suisse has downgraded Editas Medicine Inc (NASDAQ:EDIT) from Outperform to Neutral with a price target of $13 from $25. Thursday, Editas announced…